# A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer

> **NCT00882310** · PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 37 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00882310
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2016-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882310, "A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00882310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*